Show summary Hide summary
A large South Korean analysis of nearly 28,000 adults found that people who reported taking prescription drugs for weight control over the past year also reported higher rates of depression, mental-health counseling and suicidal thoughts or behaviors. The study raises fresh questions about how weight-loss treatments, weight regain and underlying mental health intersect—an issue that matters as such medicines become more widely used worldwide.
What the study found
Researchers at Asan Medical Center examined health survey data from 27,741 adults collected between 2013 and 2022. Of those, 846 said they had used prescribed medications aimed at weight control in the previous year; the remainder had not.
US sanctions Turkish bank: action targets Iran’s key funding route
Judy Harvey: who she is and what to know now
The analysis linked reported use of these drugs with greater odds of several psychiatric outcomes. Compared with non-users, people who took prescription weight-loss medication were roughly:
- 1.9 times more likely to report depression,
- 2.0 times more likely to have sought mental-health counseling,
- 2.7 times more likely to report suicidal thoughts, and
- 1.7 times more likely to report a suicide attempt.
These associations were strongest among users who later gained or regained weight, a subgroup that showed markedly higher odds of suicidal ideation compared with non-users.
How researchers and clinicians interpret the results
The paper, published Aug. 23 in the Korean Journal of Family Practice, emphasizes that the observed links do not prove the medications caused the mental-health problems.
A licensed clinical counselor who reviewed the study cautioned that it is cross-sectional—drawn from a single point in time—and therefore cannot separate symptoms that existed before treatment from those that might have developed afterwards. She also pointed out that the data largely reflect older anti-obesity drugs available during the study window, not the newer GLP-1/GIP agents that have recently attracted widespread attention.
Why the distinction matters
Between 2013 and 2022, many countries relied on older prescriptions such as phentermine, diethylpropion, phendimetrazine, topiramate and orlistat. Some of these medications act as central nervous system stimulants and have known side effects including anxiety, sleep disruption and mood changes—factors that could contribute to the patterns seen in the survey.
By contrast, modern high-dose GLP-1 receptor agonists (for example, semaglutide products) and dual GLP-1/GIP medicines were less commonly prescribed in that period in South Korea, so the new study does not directly measure the safety profile of those newer agents in real-world use.
Clinical and public-health implications
Clinicians and patients need clearer evidence to determine whether mental-health signals are drug-specific, related to the psychological effects of weight rebound, or a reflection of pre-existing vulnerability among people with obesity.
Experts recommend practical steps that can be taken now to reduce risk and detect problems early:
- Perform a baseline mental-health assessment before starting a weight-loss medication, including screening for past or current depression, bipolar disorder, or prior suicidal ideation or attempts.
- Inform patients and caregivers about possible mood changes so they know what to watch for.
- Schedule follow-up checks—commonly every 4 to 8 weeks during dose increases—to assess both physical response and psychological well-being.
- Discontinue the medication and arrange psychiatric support if a patient develops new emergent depressive symptoms or suicidal thoughts.
Warning signs patients should not ignore
If you or someone you care for is taking a prescription weight-loss drug, seek medical advice promptly for any of the following:
- Persistent low mood, profound sadness or unexplained exhaustion
- Loss of interest in activities previously enjoyed
- Marked increases in anxiety, agitation, panic or restlessness
- Significant sleep problems or new insomnia
- New or worsening thoughts of self-harm or suicide
- Noticeable personality or behavior changes reported by friends or family
Immediate action: Any active plan or intent to harm oneself requires urgent emergency care or contacting crisis services right away.
What manufacturers say
Drug makers provide different summaries of trial and post-market evidence. The manufacturer of tirzepatide (Zepbound) lists “depression or thoughts of suicide” among items to monitor in its safety information and advises patients to report worrying changes in mood or behavior.
Manufacturers of semaglutide-based weight-loss treatments report low absolute rates of suicidal ideation in clinical trials (under 1%) and, in some trials, no statistical difference versus placebo. At the same time, product labels for chronic weight-management medications commonly instruct clinicians to watch for mood changes during treatment.
What’s next
Observers say more targeted research is needed that separates drugs by class, follows people longitudinally, and controls for baseline mental-health status and weight trajectory.
Until that evidence is available, the balance of risks and benefits should be assessed individually: screening beforehand, transparent conversation about possible psychological effects, and ongoing monitoring can help clinicians and patients use these treatments more safely.
